JACC: Cardiooncology

Article	Citations
Cardiovascular Risk Factors Are Associated With Future Cancer	99
Past, Present, and Future of Radiation-Induced Cardiotoxicity: Refinements in Targeting, Surveillance, and Risk Stratification	97
Cardiovascular Manifestations From Therapeutic Radiation	88
Venous and Arterial Thromboembolism in Patients With Cancer	86
ATTR Amyloidosis: Current and Emerging Management Strategies	83
The Evolving Immunotherapy Landscape and the Epidemiology, Diagnosis, and Management of Cardiotoxicity	79
Incident Cardiovascular Disease Among Adults With Cancer	72
Immune Checkpoint Inhibitor Therapy Aggravates T Cell–Driven Plaque Inflammation in Atherosclerosis	70
Risk of Atrial Fibrillation According to Cancer Type	68
Early Cardiac Toxicity Associated With Post-Transplant Cyclophosphamide in Allogeneic Stem Cell Transplantation	67
Strain Imaging in Cardio-Oncology	64
The Role of Cardioprotection in Cancer Therapy Cardiotoxicity	61
Common Pathophysiology in Cancer, Atrial Fibrillation, Atherosclerosis, and Thrombosis	59
Immune Checkpoint Inhibitor Therapy in Oncology	58
Myocarditis Surveillance With High-Sensitivity Troponin I During Cancer Treatment With Immune Checkpoint Inhibitors	54
Mitochondria-Rich Extracellular Vesicles Rescue Patient-Specific Cardiomyocytes From Doxorubicin Injury	51
AL Amyloidosis: Current Chemotherapy and Immune Therapy Treatment Strategies	40
BSE and BCOS Guideline for Transthoracic Echocardiographic Assessment of Adult Cancer Patients Receiving Anthracyclines and/or Trastuzumab	39
Electrophysiological Manifestations of Cardiac Amyloidosis	38
Arterial Thromboembolism in Cancer Patients	38
Genetics of Anthracycline Cardiomyopathy in Cancer Survivors	35
Cancer Incidence and Mortality According to Pre-Existing Heart Failure in a Community-Based Cohort	34
Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients With Active Cancer	33
Risk of Cancer After Diagnosis of Cardiovascular Disease	33
Atherosclerosis With Immune Checkpoint Inhibitor Therapy	33

The Incidence, Risk Factors, and Outcomes With 5-Fluorouracil–Associated Coronary Vasospasm	32
Coronary Artery Disease in Young Women After Radiation Therapy for Breast Cancer	32
AL Amyloidosis for Cardiologists	32
Dual Angiotensin Receptor-Neprilysin Inhibition With Sacubitril/Valsartan Attenuates Systolic Dysfunction in Experimental Doxorubicin-Induced Cardiotoxicity	31
Low QRS Voltages in Cardiac Amyloidosis	31
Does Cardiovascular Mortality Overtake Cancer Mortality During Cancer Survivorship?	31
Temporal Trends of Wild-Type Transthyretin Amyloid Cardiomyopathy in the Transthyretin Amyloidosis Outcomes Survey	30
Cardiovascular Disease in Myeloproliferative Neoplasms	30
Biomarker Trends, Incidence, and Outcomes of Immune Checkpoint Inhibitor–Induced Myocarditis	29
Cardiometabolic Comorbidities in Cancer Survivors	28
Impact of Social Vulnerability on Comorbid Cancer and Cardiovascular Disease Mortality in the United States	27
Concomitant Transthyretin Amyloidosis and Severe Aortic Stenosis in Elderly Indian Population	27
Racial and Ethnic Disparities in Cardio-Oncology	26
Two Decades of Cardiac Amyloidosis	26
Patterns of Anticoagulation Use in Patients With Cancer With Atrial Fibrillation and/or Atrial Flutter	26
Allogeneic Mesenchymal Cell Therapy in Anthracycline-Induced Cardiomyopathy Heart Failure Patients	24
Atherosclerotic Cardiovascular Disease, Cancer, and Financial Toxicity Among Adults in the United States	24
Management of Immune Checkpoint Inhibitor–Induced Myocarditis	23
A Proteomic Atlas of Cardiac Amyloid Plaques	23
Role of Physical Activity and Cardiac Rehabilitation in Patients Undergoing Hematopoietic Stem Cell Transplantation	22
Immune Checkpoint Inhibitor Myocarditis Treatment Strategies and Future Directions	22
Mechanistic and Clinical Overview Cardiovascular Toxicity of BRAF and MEK Inhibitors	22
The Association of Sodium-Glucose Cotransporter 2 Inhibitors With Cardiovascular Outcomes in Anthracycline-Treated Patients With Cancer	21
Refining the 10-Year Prediction of Left Ventricular Systolic Dysfunction in Long-Term Survivors of Childhood Cancer	21
Lifestyle and Cardiovascular Risk Factors Associated With Heart Failure Subtypes in Postmenopausal Breast Cancer Survivors	20
Permissive Cardiotoxicity	20
Cardiovascular Toxicity of Proteasome Inhibitors: Underlying Mechanisms and Management Strategies	20
Machine Learning Identifies Clinical and Genetic Factors Associated With Anthracycline Cardiotoxicity in Pediatric Cancer Survivors	20
Cardiovascular Disease Among Patients With AML and CHIP-Related Mutations	19
Cardiac Computed Tomography in Cardio-Oncology	19
Prevalence, Treatment, and Prognosis of Tumor Thrombi in Renal Cell Carcinoma	19
How to Diagnose and Manage Patients With Fluoropyrimidine-Induced Chest Pain	19
Racial and Ethnic Disparities in All-Cause and Cardiovascular Mortality Among Cancer Patients in the U.S.	18
Immune Checkpoint Inhibitor-Associated Myocarditis With Persistent Troponin Elevation Despite Abatacept and Prolonged Immunosuppression	18
How to Diagnose and Manage QT Prolongation in Cancer Patients	18
Takotsubo Cardiomyopathy Associated With Checkpoint Inhibitor Therapy	18
The Role of Healthy Lifestyle in Cancer Incidence and Temporal Transitions to Cardiometabolic Disease	17
Screening for Coronary Artery Disease in Cancer Survivors	17
How to Treat Prostate Cancer With Androgen Deprivation and Minimize Cardiovascular Risk	17
Cardiovascular Toxicities of BTK Inhibitors in Chronic Lymphocytic Leukemia	16
Cardiotoxicity of T-Cell Antineoplastic Therapies	16
Longitudinal Strain and Troponin I Elevation in Patients Undergoing Immune Checkpoint Inhibitor Therapy	16
Reduced Cardiorespiratory Fitness and Increased Cardiovascular Mortality After Prolonged Androgen Deprivation Therapy for Prostate Cancer	16
Effect of Tafamidis on Serum Transthyretin Levels in Non-Trial Patients With Transthyretin Amyloid Cardiomyopathy	16
Optimal Timing of a Physical Exercise Intervention to Improve Cardiorespiratory Fitness	15
Oncotherapeutic Protein Kinase Inhibitors Associated With Pro-Arrhythmic Liability	15
Detection of Subclinical Cardiovascular Disease by Cardiovascular Magnetic Resonance in Lymphoma Survivors	15
How to Manage Atrial Fibrillation Secondary to Ibrutinib	15
Transcatheter Compared With Surgical Aortic Valve Replacement in Patients With Previous Chest-Directed Radiation Therapy	14
Prognosis of Transthyretin Cardiac Amyloidosis Without Heart Failure Symptoms	13

Major Adverse Cardiovascular Events in Patients With Renal Cell Carcinoma Treated With Targeted Therapies	13
Physical Activity and Cardiac Function in Long-Term Breast Cancer Survivors	13
Cardiac Magnetic Resonance for Early Detection of Radiation Therapy-Induced Cardiotoxicity in a Small Animal Model	13
Cardiac Biomarkers During Cancer Therapy	13
Clonal Hematopoiesis and JAK2V617F Mutations in Patients With Cardiovascular Disease	13
Contribution of Polygenic Risk to Hypertension Among Long-Term Survivors of Childhood Cancer	13
Prevalence of Cardiovascular Disease in Patients With Potentially Curable Malignancies	13
Impact of Cancer in Patients Undergoing Transcatheter Aortic Valve Replacement	12
Acute Effects of Ibrutinib on Ventricular Arrhythmia in Spontaneously Hypertensive Rats	12
Association of Cardiometabolic Disease With Cancer in the Community	12
Delphi Panel Consensus Recommendations for Screening and Managing Childhood Cancer Survivors at Risk for Cardiomyopathy	12
Cancer Treatment-Related Cardiovascular Toxicity in Gynecologic Malignancies	11
Cardiac Transplantation and Mechanical Circulatory Support in Amyloidosis	11
Left Atrial Mechanics Associates With Paroxysmal Atrial Fibrillation in Light-Chain Amyloidosis Following Stem Cell Transplantation	11
3-Year Follow-Up of Radiation-Associated Changes in Diastolic Function by Speckle Tracking Echocardiography	11
Pre-Existing Autoimmune Disease Increases the Risk of Cardiovascular and Noncardiovascular Events After Immunotherapy	11
Clinical, Echocardiographic, and Biomarker Associations With Impaired Cardiorespiratory Fitness Early After HER2-Targeted Breast Cancer Therapy	11
LAG3 Regulates T Cell Activation and Plaque Infiltration in Atherosclerotic Mice	10
Arterial Thromboembolism in Patients With AF and CHA2DS2-VASc Score 0-2 With and Without Cancer	10
Time-Restricted Eating to Reduce Cardiovascular Risk Among Older Breast Cancer Survivors	10
How to Manage Patients With Cardiac Implantable Electronic Devices Undergoing Radiation Therapy	10
The Burden of Uncontrolled Cardiovascular Risk Factors in Men With Prostate Cancer	10
Effectiveness and Safety of Rivaroxaban and Low Molecular Weight Heparin in Cancer-Associated Venous Thromboembolism	10
Potential Applications for Targeted Gene Therapy to Protect Against Anthracycline Cardiotoxicity	9
Self-Reported Physical Activity, QoL, Cardiac Function, and Cardiorespiratory Fitness in Women With HER2+ Breast Cancer	9
Cardiac Magnetic Resonance in Cardio-Oncology	9
Predicting Adverse Cardiac Events After Radiotherapy for Locally Advanced Non–Small Cell Lung Cancer	9
Atrial Fibrillation Incidence Associated With Exposure to Anticancer Drugs Used as Monotherapy in Clinical Trials	9
Amyloidosis and 30-Day Outcomes Among Patients With Heart Failure	9
Cardioprotection in Patients at High Risk of Anthracycline-Induced Cardiotoxicity	9
Association of Midlife Cardiovascular Health and Subsequent Change in Cardiovascular Health With Incident Cancer	9
Outcomes by Cardiac Stage in Patients With Newly Diagnosed AL Amyloidosis	9
Priorities in Cardio-Oncology Basic and Translational Science	9
Cancer-Associated Thrombosis	8
Remote Ischemic Conditioning in Pediatric Cancer Patients Receiving Anthracycline Chemotherapy	8
Considerations of Competing Risks Analysis in Cardio-Oncology Studies	8
Financial Toxicity in Cancer and Cardiovascular Disease	8
Racial Differences in Chronic Stress/Allostatic Load Variation Due to Androgen Deprivation Therapy in Prostate Cancer	8
What Is the Evidence of the Diagnostic Criteria and Screening of Immune Checkpoint Inhibitor–Induced Myocarditis?	8
Outcomes by Class of Anticoagulant Use for Nonvalvular Atrial Fibrillation in Patients With Active Cancer	8
From Cardiac Anthracycline Accumulation to Real-Life Risk for Early Diastolic Dysfunction	8
Cellular and Molecular Mechanisms of MEK1 Inhibitor–Induced Cardiotoxicity	7
Research Quality and Impact of Cardiac Rehabilitation in Cancer Survivors	7
Performance Status and Long-Term Outcomes in Cancer-Associated Pulmonary Embolism	7
Remote Ischemic Conditioning for Anthracycline Cardiotoxicity	7
Late-Onset Immunotherapy-Induced Myocarditis 2 Years After Checkpoint Inhibitor Initiation	7
Evaluation of Senescence and Its Prevention in Doxorubicin-Induced Cardiotoxicity Using Dynamic Engineered Heart Tissues	7
Reversible Myocardial Edema Secondary to Tagraxofusp-Induced Capillary Leak Syndrome	7
Anthracyclines and Biomarkers of Myocardial Injury	7
Cardiovascular Events After Hematopoietic Stem Cell Transplant	7
Successful CAR T Cell Therapy in a Heart and Kidney Transplant Recipient With Refractory PTLD	7
Physician Knowledge and Awareness About Cardiac Amyloidosis in the Middle East and Gulf Region	6
Healthy Lifestyle Benefits Both Cancer and Cardiovascular Disease	6
Cardiovascular Burden and Adverse Events in Patients With Esophageal Cancer Treated With Chemoradiation for Curative Intent	6
Validity of Estimated Cardiorespiratory Fitness in Patients With Primary Breast Cancer	6
Associations Between Social Determinants of Health and Cardiovascular Health of U.S. Adult Cancer Survivors	6
Overcoming LGBTQI+ Disparities in Cardio-Oncology	6
Cardiovascular Morbidity in Monoclonal Gammopathy of Undetermined Significance	6
Prevalence of Diastolic Dysfunction in Adult Survivors of Childhood Cancer	6
Contribution of Genome-Wide Polygenic Score to Risk of Coronary Artery Disease in Childhood Cancer Survivors	6
Cardiac Interventions in Patients With Active, Advanced Solid and Hematologic Malignancies	6
Cardiac Toxicity of Alectinib in Patients With ALK+ Lung Cancer	6
How to Perform Pericardiocentesis in Cancer Patients With Thrombocytopenia	6
Left Ventricular Assist Devices in Patients With Active Malignancies	6
Tumor Genomic Profile Is Associated With Arterial Thromboembolism Risk in Patients With Solid Cancer	6
Left Atrial Appendage Occlusion in Patients With Atrial Fibrillation and Cancer	6
Pharmacovigilance Analysis of Heart Failure Associated With Anti-HER2 Monotherapies and Combination Regimens for Cancer	6
Direct Oral Anticoagulants in Patients With Cancer and Nonvalvular Atrial Fibrillation	6
How to Diagnose and Manage Radiation Cardiotoxicity	5
The Association of Metformin With Heart Failure in Patients With Diabetes Mellitus Receiving Anthracycline Chemotherapy	5
Risk for Myocardial Infarction Following 5-Fluorouracil Treatment in Patients With Gastrointestinal Cancer	5
5-Fluorouracil Cardiotoxicity	5
Chest Pain in Cancer Patients	5
Cardio-Oncology in Japan	5
Atrial Fibrillation and Cancer	5
Atrial Involvement in Cardiac Amyloidosis	5
Outcomes of Patients With Myeloproliferative Neoplasms Admitted With Myocardial Infarction	5
Cancer Immunotherapy Beyond Checkpoint Blockade	5
Lymphoma Severity and Type Are Associated With Aortic FDG Uptake by 18F-FDG PET/CT Imaging	5
Ibrutinib Is Associated With Increased Cardiovascular Events and Major Bleeding in Older CLL Patients	5

Functional Validation of Doxorubicin-Induced Cardiotoxicity-Related Genes	5
Heart Failure Post-Myocardial Infarction Promotes Mammary Tumor Growth Through the NGF-TRKA Pathway	5
Cisplatin-Associated Aortic Thrombosis	5
Combat Doxorubicin Cardiotoxicity With the Power of Mitochondria Transfer	5
ESC Cardio-Oncology Guidelines	5
Anticoagulation for the Prevention of Arterial Thrombosis in Ambulatory Cancer Patients	5
Extensive Cardiac Function Analyses Using Contemporary Echocardiography in Childhood Cancer Survivors	5
Heart Transplantation in Adriamycin-Associated Cardiomyopathy in the Contemporary Era of Advanced Heart Failure Therapies	5
Radiation-Associated Coronary Disease in Young Cancer Survivors	5